In vitro activity of cefpirome against microorganisms isolated in haematology, oncology and intensive care units in Switzerland

Détails

ID Serval
serval:BIB_C743E4F3E236
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
In vitro activity of cefpirome against microorganisms isolated in haematology, oncology and intensive care units in Switzerland
Périodique
Scandinavian Journal of Infectious Diseases
Auteur(s)
Liassine  N., Bille  J., Breer  C., Frei  R., Wust  J., Auckenthaler  R.
ISSN
0036-5548
Statut éditorial
Publié
Date de publication
1997
Peer-reviewed
Oui
Volume
29
Numéro
6
Pages
615-21
Notes
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Résumé
The in vitro activity of cefpirome, a new parenteral fourth-generation cephalosporin, was investigated in the 5 university hospitals of Switzerland, and compared to 9 other antibiotics mainly used in hospitals, such as ceftazidime, ceftriaxone, cefotaxime, piperacillin, imipenem, gentamicin, vancomycin, ciprofloxacin and ofloxacin. A total number of 992 strains collected only from intensive care units and haematology-oncology units were tested by microdilution according to NCCLS. Cefpirome showed an excellent activity against all Enterobacteriaceae (MIC90 = 4 mg/l), methicillin-susceptible staphylococci (MIC90 = 1 mg/l), Streptococcus pneumoniae (MIC90 = 0.25 mg/l) and Haemophilus influenzae (MIC90 = 0.12 mg/l) isolates. Its activity was superior to that of third-generation cephalosporins against cephalosporinase-depressed mutants of Enterobacter cloacae and Citrobacter freundii isolates (MIC90 > 32 mg/l for third-generation cephalosporins vs 4 mg/l for cefpirome). The MICs of cefpirome of 3 strains of Klebsiella spp. with an extended-spectrum-beta-lactamase were lower (MIC90 = 2 mg/l) than those of third-generation cephalosporins (MICs90 > 32 mg/l). Against Pseudomonas aeruginosa cefpirome was as active as ceftazidime. The activity of cefpirome was poor against methicillin-resistant staphylococci, enterococci and nosocomial Gram-negative bacteria such as Stenotrophomonas maltophilia.
Mots-clé
Anti-Bacterial Agents/therapeutic use Bacteria/*drug effects/growth & development Cephalosporinase/adverse effects Cephalosporins/*pharmacology Drug Resistance, Microbial Hospital Units Humans Intensive Care Units Methicillin Resistance Microbial Sensitivity Tests Staphylococcus/drug effects Switzerland/epidemiology
Pubmed
Web of science
Création de la notice
11/02/2008 13:39
Dernière modification de la notice
03/03/2018 21:19
Données d'usage